Nyt fra tidsskrifterne
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Klik på knappen for at kopiere eller tryk på linket nedenfor.
Kopieret til udklipsholder!
Ingen søgeord valgt.
46 emner vises.
Fouad Chouairi, Edward Jaffe, Abdul Mannan Khan Minhas, Marat Fudim
PLoS One Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
by Fouad Chouairi, Edward Jaffe, Abdul Mannan Khan Minhas, Marat Fudim Background The COVID-19 pandemic has stretched healthcare resources thin and led to significant morbidity and mortality. There have been no studies utilizing national data to investigate the role of cardiac risk factors on outcomes of COVID hospitalizations. The aim of this study was to examine the effect of cardiac multimorbidity on healthcare utilization and outcomes among COVID hospitalizations during the first year of the pandemic. Methods Using the national inpatient sample (NIS), we identified all adult hospital admissions with a primary diagnosis of COVID in 2020, using International Classification of Diseases, Tenth Revision, Clinical Modification codes (ICD010-CM). Coronary artery disease, diabetes mellitus, heart failure, peripheral vascular disease, previous stroke, and atrial fibrillation were then identified as cardiac comorbidities using ICD-10-CM codes. Multivariable logistic regression was used to evaluate the effect of cardiac multimorbidity on mortality and mechanical ventilation. Results We identified 1,005,040 primary COVID admissions in 2020. Of these admissions, 216,545 (20.6%) had CAD, 413,195 (39.4%) had DM, 176,780 (16.8%) had HF, 159,700 (15.2%) had AF, 30735 (2.9%) had PVD, and 25,155 (2.4%) had a previous stroke. When stratified by number of comorbidities, 428390 (40.8%) had 0 comorbidities, 354960 (33.8%) had 1, 161225 (15.4%) had 2, and 105465 (10.0%) had 3+ comorbidities. COVID hospitalizations with higher cardiac multimorbidity had higher mortality rates (p
Læs mere Tjek på PubMedFang Fang, John David Clemens, Zuo-Feng Zhang, Timothy F. Brewer
PLoS One Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
by Fang Fang, John David Clemens, Zuo-Feng Zhang, Timothy F. Brewer Background Given the waning of vaccine effectiveness and the shifting of the most dominant strains in the U.S., it is imperative to understand the association between vaccination coverage and Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) disease and mortality at the community levels and whether that association might vary according to the dominant SARS-CoV-2 strains in the U.S. Methods Generalized estimating equations were used to estimate associations between U.S. county-level cumulative vaccination rates and booster distribution and the daily change in county-wide Coronavirus 2019 disease (COVID-19) risks and mortality during Alpha, Delta and Omicron predominance. Models were adjusted for potential confounders at both county and state level. A 2-week lag and a 4-week lag were introduced to assess vaccination rate impact on incidence and mortality, respectively. Results Among 3,073 counties in 48 states, the average county population complete vaccination rate of all age groups was 50.79% as of March 11th, 2022. Each percentage increase in vaccination rates was associated with reduction of 4% (relative risk (RR) 0.9607 (95% confidence interval (CI): 0.9553, 0.9661)) and 3% (RR 0.9694 (95% CI: 0.9653, 0.9736)) in county-wide COVID-19 cases and mortality, respectively, when Alpha was the dominant variant. The associations between county-level vaccine rates and COVID-19 incidence diminished during the Delta and Omicron predominance. However, each percent increase in people receiving a booster shot was associated with reduction of 6% (RR 0.9356 (95% CI: 0.9235, 0.9479)) and 4% (RR 0.9595 (95% CI: 0.9431, 0.9761)) in COVID-19 incidence and mortality in the community, respectively, during the Omicron predominance. Conclusions Associations between complete vaccination rates and COVID-19 incidence and mortality appeared to vary with shifts in the dominant variant, perhaps due to variations in vaccine efficacy by variant or to waning vaccine immunity over time. Vaccine boosters were associated with notable protection against Omicron disease and mortality.
Læs mere Tjek på PubMedHadil Alahdal, Ghaida Almuneef, Manal Muhammed Alkhulaifi, Omar Aldibasi, Abdulrahman Aljouie, Othman Alharbi, Zakiah Naser Almohawes, Fatemah Basingab, Mokhtar Rejili
PLoS One Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
by Hadil Alahdal, Ghaida Almuneef, Manal Muhammed Alkhulaifi, Omar Aldibasi, Abdulrahman Aljouie, Othman Alharbi, Zakiah Naser Almohawes, Fatemah Basingab, Mokhtar Rejili Crohn’s disease (CD) entails intricate interactions with gut microbiome diversity, richness, and composition. The relationship between CD and gut microbiome is not clearly understood and has not been previously characterized in Saudi Arabia. We performed statistical analysis about various factors influencing CD activity and microbiota dysbiosis, including diagnosis, treatment, and its impact on their quality of life as well as high-throughput metagenomic V3-V4 16S rRNA encoding gene hypervariable region of a total of eighty patients with CD, both in its active and inactive state with healthy controls. The results were correlated with the demographic and lifestyle information, which the participants provided via a questionnaire. α-diversity measures indicated lower bacterial diversity and richness in the active and inactive CD groups compared to the control group. Greater dysbiosis was observed in the active CD patients compared to the inactive form of the disease, showed by a reduction in microbial diversity. Specific pathogenic bacteria such as Filifactor, Peptoniphilus, and Sellimonas were identified as characteristic of CD groups. In contrast, anti-inflammatory bacteria like Defluviitalea, Papillibacter, and Petroclostridium were associated with the control group. Among the various factors influencing disease activity and microbiota dysbiosis, smoking emerged as the most significant, with reduced α-diversity and richness for the smokers in all groups, and proinflammatory Fusobacteria was more present (p
Læs mere Tjek på PubMedTao-Qian Tang, Rashid Jan, Zahir Shah, Narcisa Vrinceanu, Ciprian Tanasescu, Asif Jan
PLoS One Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
by Tao-Qian Tang, Rashid Jan, Zahir Shah, Narcisa Vrinceanu, Ciprian Tanasescu, Asif Jan Infectious disease cryptosporidiosis is caused by the cryptosporidium parasite, a type of parasitic organism. It is spread through the ingestion of contaminated water, food, or fecal matter from infected animals or humans. The control becomes difficult because the parasite may remain in the environment for a long period. In this work, we constructed an epidemic model for the infection of cryptosporidiosis in a fractional framework with strong and weak immunity concepts. In our analysis, we utilize the well-known next-generation matrix technique to evaluate the reproduction number of the recommended model, indicated by R 0. As R 0 < 1, our results show that the disease-free steady-state is locally asymptotically stable; in other cases, it becomes unstable. Our emphasis is on the dynamical behavior and the qualitative analysis of cryptosporidiosis. Moreover, the fixed point theorem of Schaefer and Banach has been utilized to investigate the existence and uniqueness of the solution. We identify suitable conditions for the Ulam-Hyers stability of the proposed model of the parasitic infection. The impact of the determinants on the sickness caused by cryptosporidiosis is highlighted by the examination of the solution pathways using a novel numerical technique. Numerical investigation is conducted on the solution pathways of the system while varying various input factors. Policymakers and health officials are informed of the crucial factors pertaining to the infection system to aid in its control.
Læs mere Tjek på PubMedInternational Journal for Parasitology, 24.04.2024
Tilføjet 24.04.2024
Publication date: Available online 23 April 2024 Source: International Journal for Parasitology Author(s): Ľubomíra Chmelová, Natalya Kraeva, Andreu Saura, Adam Krayzel, Cecilia Stahl Vieira, Tainá Neves Ferreira, Rodrigo Pedro Soares, Barbora Bučková, Arnau Galan, Eva Horáková, Barbora Vojtková, Jovana Sádlová, Marina N. Malysheva, Anzhelika Butenko, Galina Prokopchuk, Alexander O. Frolov, Julius Lukeš, Anton Horváth, Ingrid Škodová-Sveráková, Denise Feder
Læs mere Tjek på PubMedCurrent Opinion in Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Stevens, Dennis L.
Current Opinion in Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Naughton, Patrick; Enright, Frances; Lucey, Brigid
Current Opinion in Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Purpose of review Infectious mononucleosis (IM) is an infectious disease that presents clinically in only a small percentage of individuals despite almost universal infection with the causative agent. Here, we review the latest concepts in the clinical presentation, epidemiology, and host response of this disease. Recent findings Several recently published papers/reviews describe IM as a condition caused by one of several etiologic agents including, cytomegalovirus (HHV-5), Roseola virus (HHV-6) and Toxoplasmosis amongst others; this review focuses on IM as solely caused by the human herpes virus 4 (HHV-4). Since the initial discovery of the virus in the 1960s and its subsequent discovery as the primary etiologic agent for IM it has been associated with several human cancers and autoimmune disorders. Recent published findings show a correlation between HHV-4 and the autoimmune disorder, multiple sclerosis (MS), suggesting earlier IM could possibly act as a causative factor. Considering the important links being made with IM to so many cancers and autoimmune disorders it is surprising that a standard investigative procedure has yet to be determined for this disease. A standard approach to the investigation of IM would ensure more cases are diagnosed, particularly atypical cases, this would benefit epidemiological studies, and more immediately help practitioners distinguish viral from bacterial throat infections, enabling them to treat accordingly. Summary The understanding of the latest concepts in clinical presentation, epidemiology and host response to IM would benefit greatly from the introduction of a standard procedure for its investigation and diagnosis.
Læs mere Tjek på PubMedSanford, Tristan C.; Tweten, Rodney K.; Abrahamsen, Hunter L.
Current Opinion in Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Purpose of review Many cholesterol-dependent cytolysin (CDC)-producing pathogens pose a significant threat to human health. Herein, we review the pore-dependent and -independent properties CDCs possess to assist pathogens in evading the host immune response. Recent findings Within the last 5 years, exciting new research suggests CDCs can act to inhibit important immune functions, disrupt critical cell signaling pathways, and have tissue-specific effects. Additionally, recent studies have identified a key region of CDCs that generates robust immunity, providing resources for the development of CDC-based vaccines. Summary This review provides new information on how CDCs alter host immune responses to aid bacteria in pathogenesis. These studies can assist in the design of more efficient vaccines and therapeutics against CDCs that will enhance the immune response to CDC-producing pathogens while mitigating the dampening effects CDCs have on the host immune response.
Læs mere Tjek på PubMedHoward, Leigh M.; Grijalva, Carlos G.
Current Opinion in Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Purpose of review Prevention of acute respiratory illnesses (ARI) in children is a global health priority, as these remain a leading cause of pediatric morbidity and mortality throughout the world. As new products and strategies to prevent respiratory infections caused by important pathogens such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza, respiratory syncytial virus and pneumococcus are advancing, increasing evidence suggests that these and other respiratory viruses and pneumococci may exhibit interactions that are associated with altered colonization and disease dynamics. We aim to review recent data evaluating interactions between respiratory viruses and pneumococci in the upper respiratory tract and their potential impact on pneumococcal colonization patterns and disease outcomes. Recent findings While interactions between influenza infection and subsequent increased susceptibility and transmissibility of colonizing pneumococci have been widely reported in the literature, emerging evidence suggests that human rhinovirus, SARS-CoV-2, and other viruses may also exhibit interactions with pneumococci and alter pneumococcal colonization patterns. Additionally, colonizing pneumococci may play a role in modifying outcomes associated with respiratory viral infections. Recent evidence suggests that vaccination with pneumococcal conjugate vaccines, and prevention of colonization with pneumococcal serotypes included in these vaccines, may be associated with reducing the risk of subsequent viral infection and the severity of the associated illnesses. Summary Understanding the direction and dynamics of viral-pneumococcal interactions may elucidate the potential effects of existing and emerging viral and bacterial vaccines and other preventive strategies on the health impact of these important respiratory pathogens.
Læs mere Tjek på PubMedMichels, Sarah Y.; Daley, Matthew F.; Newcomer, Sophia R.
Current Opinion in Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Purpose of review Completion of all doses in multidose vaccine series provides optimal protection against preventable infectious diseases. In this review, we describe clinical and public health implications of multidose vaccine series noncompletion, including current challenges to ensuring children receive all recommended vaccinations. We then highlight actionable steps toward achieving early childhood immunization goals. Recent findings Although coverage levels are high for most early childhood vaccinations, rates of completion are lower for vaccinations that require multiple doses. Recent research has shown that lower family socioeconomic status, a lack of health insurance coverage, having multiple children in the household, and moving across state lines are associated with children failing to complete multidose vaccine series. These findings provide contextual evidence to support that practical challenges to accessing immunization servi ces are impediments to completion of multidose series. Strategies, including reminder/recall, use of centralized immunization information systems, and clinician prompts, have been shown to increase immunization rates. Re-investing in these effective interventions and modernizing the public health infrastructure can facilitate multidose vaccine series completion. Summary Completion of multidose vaccine series is a challenge for immunization service delivery. Increased efforts are needed to address remaining barriers and improve vaccination coverage in the United States.
Læs mere Tjek på PubMedStrong, Nora; Ostrosky-Zeichner, Luis
Current Opinion in Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Purpose of review Fusarium species are an increasingly important cause of meningitis and invasive disease in immunocompromised patients as well as in otherwise healthy patients as observed in two recent healthcare-associated outbreaks. This review summarizes recently published information on treatment and diagnosis of this infection. Recent findings Incidence of Fusarium species meningitis and invasive fusariosis are increasing. Molecular techniques are improving the speed of diagnosis. New antifungal agents in development show good in vitro activity against some Fusarium species. New technologies, including cerebrospinal fluid (CSF) filtration, may play a role in treatment of central nervous system (CNS) disease. Due to the continued prime importance of the host immune system in recovery, immunomodulatory treatments may play a role in treatment. Summary The overall incidence of CNS fusariosis is increasing with a continued poor prognosis, but new diagnostic and treatment modalities are in development which may offer improvements.
Læs mere Tjek på PubMedMorado-Aramburo, Oscar; Hasbun, Rodrigo
Current Opinion in Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Purpose of review Central nervous system (CNS) infections in solid organ transplant (SOT) recipients may present atypical or nonspecific symptoms. Due to a wider range of infectious agents compared with immunocompetent hosts, diagnosis is challenging. This review categorizes CNS infections in SOT recipients by cause. Recent findings New studies have reported new data on the epidemiology and the risk factors associated with each specific pathogen described in this review. Additionally, we included the treatment recommendations. Summary The latest findings give us an insight into the different pathogens causing infectious neurologic complications in SOT recipients.
Læs mere Tjek på PubMedT, Angel Miraclin; Singh, Bhagteshwar; Rupali, Priscilla
Current Opinion in Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Purpose of review Emerging and re-emerging central nervous system (CNS) infections are a major public health concern in the tropics. The reasons for this are myriad; climate change, rainfall, deforestation, increased vector density combined with poverty, poor sanitation and hygiene. This review focuses on pathogens, which have emerged and re-emerged, with the potential for significant morbidity and mortality. Recent findings In recent years, multiple acute encephalitis outbreaks have been caused by Nipah virus, which carries a high case fatality. Arboviral infections, predominantly dengue, chikungunya and Zika are re-emerging increasingly especially in urban areas due to changing human habitats, vector behaviour and viral evolution. Scrub typhus, another vector borne disease caused by the bacterium Orientia tsutsugamushi, is being established as a leading cause of CNS infections in the tropics. Summary A syndromic and epidemiological approach to CNS infections in the tropics is essential to plan appropriate diagnostic tests and management. Rapid diagnostic tests facilitate early diagnosis and thus help prompt initiation and focusing of therapy to prevent adverse outcomes. Vector control, cautious urbanization and deforestation, and reducing disturbance of ecosystems can help prevent spread of vector-borne diseases. Regional diagnostic and treatment approaches and specific vaccines are required to avert morbidity and mortality.
Læs mere Tjek på PubMedOmland, Lars Haukali; Nielsen, Henrik; Bodilsen, Jacob
Current Opinion in Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Purpose of review The epidemiology of brain abscess has changed in recent decades. Moreover, acute and long-term management remains challenging with high risks of mortality and neurological sequelae. This review describes recent advances in epidemiology, diagnosis, and treatment of brain abscess. Recent findings The incidence of brain abscess is increasing, especially among elderly individuals. Important predisposing conditions include dental and ear-nose-throat infections, immuno-compromise, and previous neurosurgery. Molecular-based diagnostics have improved our understanding of the involved microorganisms and oral cavity bacteria including anaerobes are the predominant pathogens. The diagnosis relies upon a combination of magnetic resonance imaging, neurosurgical aspiration or excision, and careful microbiological examinations. Local source control by aspiration or excision of brain abscess combined with long-term antimicrobials are cornerstones of treatment. Long-term management remains important and should address neurological deficits including epilepsy, timely diagnosis and management of comorbidities, and potential affective disorders. Summary A multidisciplinary approach to acute and long-term management of brain abscess remains crucial and source control of brain abscess by neurosurgery should be pursued whenever possible. Numerous aspects regarding diagnosis and treatment need clarification. Nonetheless, our understanding of this complicated infection is rapidly evolving.
Læs mere Tjek på PubMedMacKay, Conor I.; Kuthubutheen, Jafri; Campbell, Anita J.
Current Opinion in Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Purpose of review With cochlear implantation becoming increasingly performed worldwide, an understanding of the risk factors, preventive measures, and management of cochlear implant (CI) infection remains important given the significant morbidity and cost it conveys. Recent findings At the turn of the 21st century there was a decrease in rates of CI infection, particularly meningitis, following the discontinuation of positioner use for CI. However, in more recent years rates of CI infection have remained largely static. Recently, studies evaluating preventive measures such as pneumococcal vaccination, S. aureus decolonization and surgical antibiotic prophylaxis have emerged in the literature. Summary Prompt recognition of CI infection and appropriate investigation and management are key, however at present treatment is largely informed by cohort and case-control studies and expert opinion. Preventive measures including pneumococcal vaccination, S. aureus decolonization and preoperative antibiotic prophylaxis play a role in reducing rates of CI infection. However, there remains a need for well designed clinical trials to provide higher level evidence to better guide preventive measures for, and management decisions of, CI infections in the future.
Læs mere Tjek på PubMedLaura Butragueño-LaisecaIñaki F. TroconizSantiago GrauNuria CampilloBelén PadillaSarah Nicole FernándezMaría SlöckerLaura HerreraMaría José Santiago1Pediatric Intensive Care Unit, Hospital General Universitario Gregorio Marañón, Madrid, Spain2Gregorio Marañón Health Research Institute (IISGM), Madrid, Spain3Pediatrics Department, Universidad Complutense de Madrid, Madrid, Spain4Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Development Origin Network (RICORS) RD21/0012/0011, Carlos III Health Institute, Madrid, Spain5Pharmacometrics and Systems Pharmacology Research Unit, Department of Pharmaceutical Sciences, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain6IdiSNA, Navarra Institute for Health Research, Pamplona, Spain7Pharmacy Department, Hospital del Mar, Universitat Autònoma de Barcelona, Barcelona, Spain8Clinical Microbiology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, Andreas H. Groll
Antimicrobial Agents And Chemotherapy, 24.04.2024
Tilføjet 24.04.2024
Barbara A. Brown-ElliottGeorgie BushM. Dolores HughesEliana RodriguezChase A. WeikelSharon B. MinRichard J. Wallace1The University of Texas Health Science Center at Tyler, Mycobacteria/Nocardia Laboratory, The University of Texas at Tyler School of Medicine, Tyler, Texas, USA2Department of Infectious Diseases, GSK, Collegeville, Pennsylvania, USA, Jared A. Silverman
Antimicrobial Agents And Chemotherapy, 24.04.2024
Tilføjet 24.04.2024
Emerging Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Emerging Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
A high index of suspicion, comprehensive travel and epidemiologic history, and clinical evaluation are essential.
Læs mere Tjek på PubMedEmerging Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Supportive treatment remains the standard of care; scarce evidence supports off-label use of ribavirin and favipiravir for human benefit.
Læs mere Tjek på PubMedEmerging Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Emerging Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Research Letter - Sporotrichosis Cluster in Domestic Cats and Veterinary Technician, Kansas, USA, 2022
Læs mere Tjek på PubMedEmerging Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Research - COVID-19 Vaccination Site Accessibility, United States, December 11, 2020-March 29, 2022
Læs mere Tjek på PubMedBalogun, F. M., Omotade, O.
BMJ Open, 24.04.2024
Tilføjet 24.04.2024
ObjectivesParticipants’ comprehension of research process affects the quality of research output, which is the reason why translation of research instruments into local languages is standard practice. Literature has consistently reported that in Africa, knowledge about cervical cancer is low but paradoxically, expressed, and actual uptake of human papillomavirus vaccine for its prevention is high. This study explored the Yoruba names of cervical cancer among Yoruba people in Ibadan, Nigeria to guide the translation of cervical cancer research instruments to Yoruba language. DesignExploratory case study design was used and data were obtained with 10 in-depth interviews and four focused group discussions. Data were analysed using content analysis. SettingsThe study took place in Ibadan North local government area, Southwest Nigeria. ParticipantsThese were 4 traditional healers, 3 Yoruba linguists, 3 public health educators and 38 parents of adolescents. MeasuresThese were Yoruba names for cervical cancer and their meanings. ResultsParticipants were aware of cervical cancer but only the traditional healers and public health educators had names for it. These names were highly varied. The public health educators gave names that were linked with different parts of the female reproductive system and external genital which were actually different medical conditions. Each traditional healer also had different names for cervical cancer, which either described the female body parts, or symptoms of female genital infections. These various names can lead to unnecessary misconceptions and misinformation about cervical cancer, its prevention, management, and research. ConclusionsThere was no consensus Yoruba name for cervical cancer among the study participants. Efforts to educate the Yoruba speaking populace about cervical cancer, its prevention, management and participation in its research can be frustrated if a generally accepted Yoruba name is not provided for this cancer. Stakeholders’ collaboration is required to get an appropriate Yoruba name for cervical cancer.
Læs mere Tjek på PubMedWatjer, R. M., Heckmans, K. M., Eekhof, J. A., Gummi, L., Quint, K. D., Numans, M. E., Bonten, T. N.
BMJ Open, 24.04.2024
Tilføjet 24.04.2024
IntroductionDiabetic foot ulcers are feared complications of diabetes mellitus (DM), requiring extensive treatment and hospital admissions, ultimately leading to amputation and increased mortality. Different factors contribute to the development of foot ulcers and related complications. Onychomycosis, being more prevalent in patients with diabetes, could be an important risk factor for developing ulcers and related infections. However, the association between onychomycosis and diabetic complications has not been well studied in primary care. Research design and methodsTo determine the impact of onychomycosis on ulcer development and related complications in patients with diabetes in primary care, a longitudinal cohort study was carried out using routine care data from the Extramural Leiden University Medical Center Academic Network. Survival analyses were performed through Cox proportional hazards models with time-dependent covariates. ResultsData from 48 212 patients with a mean age of 58 at diagnosis of DM, predominantly type 2 (87.8%), were analysed over a median follow-up of 10.3 years. 5.7% of patients developed an ulcer. Onychomycosis significantly increased the risk of ulcer development (HR 1.37, 95% CI 1.13 to 1.66), not affected by antimycotic treatment, nor after adjusting for confounders (HR 1.23, 95% CI 1.01 to 1.49). The same was found for surgical interventions (HR 1.54, 95% CI 1.35 to 1.75) and skin infections (HR 1.48, CI 95% 1.28 to 1.72), again not affected by treatment and significant after adjusting for confounders (HR 1.32, 95% CI 1.16 to 1.51 and HR 1.27, 95% CI 1.10 to 1.48, respectively). ConclusionsOnychomycosis significantly increased the risk of ulcer development in patients with DM in primary care, independently of other risk factors. In addition, onychomycosis increased the risk of surgeries and infectious complications. These results underscore the importance of giving sufficient attention to onychomycosis in primary care and corresponding guidelines. Early identification of onychomycosis during screening and routine care provides a good opportunity for timely recognition of increased ulcer risk.
Læs mere Tjek på PubMedTunnicliffe, L., Muzambi, R., Bartlett, J. W., Howe, L., Abdul Basit, K., Warren-Gash, C.
BMJ Open, 24.04.2024
Tilføjet 24.04.2024
IntroductionTelomeres are a measure of cellular ageing with potential links to diseases such as cardiovascular diseases and cancer. Studies have shown that some infections may be associated with telomere shortening, but whether an association exists across all types and severities of infections and in which populations is unclear. Therefore we aim to collate available evidence to enable comparison and to inform future research in this field. Methods and analysisWe will search for studies involving telomere length and infection in various databases including MEDLINE (Ovid interface), EMBASE (Ovid interface), Web of Science, Scopus, Global Health and the Cochrane Library. For grey literature, the British Library of electronic theses databases (ETHOS) will be explored. We will not limit by study type, geographical location, infection type or method of outcome measurement. Two researchers will independently carry out study selection, data extraction and risk of bias assessment using the ROB2 and ROBINS-E tools. The overall quality of the studies will be determined using the Grading of Recommendations Assessment, Development and Evaluation criteria. We will also evaluate study heterogeneity with respect to study design, exposure and outcome measurement and if there is sufficient homogeneity, a meta-analysis will be conducted. Otherwise, we will provide a narrative synthesis with results grouped by exposure category and study design. Ethics and disseminationThe present study does not require ethical approval. Results will be disseminated via publishing in a peer-reviewed journal and conference presentations. PROSPERO registration numberCRD42023444854.
Læs mere Tjek på PubMedSano, M., Toyota, T., Morimoto, T., Noguchi, Y., Shigeno, R., Murai, R., Okada, T., Sasaki, Y., Taniguchi, T., Kim, K., Kobori, A., Ehara, N., Kinoshita, M., Doi, A., Tomii, K., Kihara, Y., Furukawa, Y.
BMJ Open, 24.04.2024
Tilføjet 24.04.2024
ObjectiveThere is a need for a robust tool to stratify the patient’s risk with COVID-19. We assessed the prognostic values of cardiac biomarkers for COVID-19 patients. MethodsThis is a single-centre retrospective cohort study. Consecutive laboratory-confirmed COVID-19 patients admitted to the Kobe City Medical Center General Hospital from July 2020 to September 2021 were included. We obtained cardiac biomarker values from electronic health records and institutional blood banks. We stratified patients with cardiac biomarkers as high-sensitive troponin I (hsTnI), N-terminal pro-B-type natriuretic peptide (NT-proBNP), creatine kinase (CK) and CK myocardial band (CK-MB), using the clinically relevant thresholds. Prespecified primary outcome measure was all-cause death. ResultsA total of 917 patients were included. hsTnI, NT-proBNP, CK and CK-MB were associated with the significantly higher cumulative 30-day incidence of all-cause death (hsTnI:
Læs mere Tjek på PubMedLin, B., Middleton, R. R., Terefe, B., Appleton, A. A., Feingold, B. J., Lynch, T., Pieterse, A. L., Rogers, R., Armah, A. E., Bierce, L. F., Flagg, A. M., McCarthy, S.
BMJ Open, 24.04.2024
Tilføjet 24.04.2024
IntroductionIn the USA, Black birthing people and infants experience disproportionately worse pregnancy-related health outcomes. The causes for these disparities are unknown, but evidence suggests that they are likely socially and environmentally based. Efforts to identify the determinants of these racial disparities are urgently needed to elucidate the highest priority targets for intervention. The Birth and Beyond (BABY) study evaluates how micro-level (eg, interpersonal and family) and macro-level (eg, neighbourhood and environmental) risk and resiliency factors transact to shape birth person-infant health, and underlying psychobiological mechanisms. Methods and analysisThe BABY study will follow 350 Black families (birthing parents, non-birthing parents and infants) from pregnancy through the first postpartum year, with research visits during pregnancy and at infant ages 6 and 12 months. Research visits comprise a combination of interview about a range of recent and life course stress and resiliency exposures and supports, psychophysiological (sympathetic, parasympathetic and adrenocortical) assessment and behavioural observations of parent–infant coregulatory behaviours. Spatial analyses are completed by mapping parent current and past residential addresses onto archival public data (eg, about neighbourhood quality and racial segregation). Finally, EMRs are abstracted for information about birthing parent relevant medical history, pregnancy conditions and infant birth outcomes. Analyses will evaluate the risk and resiliency mechanisms that contribute to pregnancy and birth-related outcomes for Black birthing people and their infants, and the protective role of individual, familial, cultural, and community supports. Ethics and disseminationThe BABY study has been approved by the Institutional Review Board at Albany Medical Centre. The study team consulted with local organisations and groups comprised of stakeholders and community leaders and continues to do so throughout the study. Research results will be disseminated with the scientific and local community as appropriate.
Læs mere Tjek på PubMedFredric CarlssonLars RåbergaDepartment of Biology, Lund University, Lund 223 62, Sweden
Proceedings of the National Academy of Sciences, 24.04.2024
Tilføjet 24.04.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 17, April 2024.
Læs mere Tjek på PubMedHozaifa MetwallyMaha M. ElbrashyTatsuhiko OzawaKazuki OkuyamaJason T. WhiteJanyerkye TulyeuJonas Nørskov SøndergaardJames Badger WingArisa MuratsuHisatake MatsumotoMasahito IkawaHiroyuki KishiIchiro TaniuchiTadamitsu KishimotoaLaboratory of Immune Regulation, The World Premier International Research Center Initiative, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, JapanbBiochemistry Department, Biotechnology Research Institute, National Research Center, Giza P.O. 12622, EgyptcDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama 930-0194, JapandLaboratory for Transcriptional Regulation, RIKEN Center for Integrative Medical Sciences, Tsurumi-ku, Yokohama, Kanagawa 230-0045, JapaneLaboratory of Experimental Immunology, The World Premier International Research Center Initiative, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, JapanfHuman Immunology Team, Center for Infectious Disease Education and Research, Osaka University, Suita 565-0871, JapangLaboratory of Human Single Cell Immunology, The World Premier International Research Center Initiative, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, JapanhDepartment of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka 565-0871, JapaniResearch Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan
Proceedings of the National Academy of Sciences, 24.04.2024
Tilføjet 24.04.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 17, April 2024.
Læs mere Tjek på PubMedWitold PostekKlaudia StaśkiewiczElin LiljaBartłomiej WacławaDioscuri Centre for Physics and Chemistry of Bacteria, Institute of Physical Chemistry, Polish Academy of Sciences, Warszawa 01-224, PolandbBroad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02142cSchool of Physics and Astronomy, The University of Edinburgh, Edinburgh EH9 3FD, United Kingdom
Proceedings of the National Academy of Sciences, 24.04.2024
Tilføjet 24.04.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 17, April 2024.
Læs mere Tjek på PubMedKavita DeJuan M. BelardinelliArun Prasad PanduranganTeddy EhianetaElena LianZuzana PalčekováHa LamMercedes Gonzalez-JuarreroJosephine M. BryantTom L. BlundellJulian ParkhillR. Andres FlotoTodd L. LowaryWilliam H. WheatMary JacksonaMycobacteria Research Laboratories, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523-1682bVictor Phillip Dahdaleh Heart and Lung Research Institute, Biomedical Campus, Trumpington, Cambridge CB2 OBB, United KingdomcInstitute of Biological Chemistry, Academia Sinica, Nangang, Taipei 11529, TaiwandParasites and Microbes Programme, Wellcome Sanger Institute, Hinxton CB10 1SA, United KingdomeDepartment of Veterinary Medicine, University of Cambridge, Cambridge CB3 0ES, United KingdomfMolecular Immunity Unit, Department of Medicine, Medical Research Council-Laboratory of Molecular Biology, University of Cambridge, Trumpington, Cambridge CB2 0QH, United KingdomgUniversity of Cambridge Centre for AI in Medicine, Cambridge CB3 0WA, United KingdomhCambridge Centre for Lung Infection, Royal Papworth Hospital, Cambridge CB2 0AY, United KingdomiInstitute of Biochemical Sciences, National Taiwan University, Taipei 106, Taiwan
Proceedings of the National Academy of Sciences, 24.04.2024
Tilføjet 24.04.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 17, April 2024.
Læs mere Tjek på PubMedGang ChenQingxia HanWan-Xiang LiRong HaiShou-Wei DingaDepartment of Microbiology and Plant Pathology, University of California, Riverside, CA 92521
Proceedings of the National Academy of Sciences, 24.04.2024
Tilføjet 24.04.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 17, April 2024.
Læs mere Tjek på PubMedNiels JohannesenAlessandro Tang-Andersen MartinelloBjørn Bjørnsson MeyerEmil Toft VestergaardAsger Lau AndersenThais Lærkholm JensenaSaïd Business School, Oxford University, Oxford OX1 1HP, United KingdombDepartment of Economics, University of Copenhagen, Copenhagen K 1353, DenmarkcCenter for Economic Behavior and Inequality, University of Copenhagen, Copenhagen K 1353, DenmarkdDanmarks Nationalbank, Copenhagen Ø 2100, Denmark
Proceedings of the National Academy of Sciences, 24.04.2024
Tilføjet 24.04.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 17, April 2024.
Læs mere Tjek på PubMedAri S. FreedmanJustin K. SheenStella TsaiJihong YaoEdward LifshitzDavid AdinaroSimon A. LevinBryan T. GrenfellC. Jessica E. MetcalfaDepartment of Ecology and Evolutionary Biology, Princeton University, Princeton, NJ 08544bNew Jersey Department of Health, Trenton, NJ 08625
Proceedings of the National Academy of Sciences, 24.04.2024
Tilføjet 24.04.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 17, April 2024.
Læs mere Tjek på PubMedSheng ShuYuko TsutsuiRajkanwar NathawatWei MiaDepartment of Pharmacology, Yale University School of Medicine, New Haven, CT 06520bCancer Biology Institute, Yale University, West Haven, CT 06516cDepartment of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06520
Proceedings of the National Academy of Sciences, 24.04.2024
Tilføjet 24.04.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 17, April 2024.
Læs mere Tjek på PubMedVictoria ChevéeKarthik HullahalliKatherine G. DaileyLeslie GüerecaChenyu ZhangMatthew K. WaldorDaniel A. PortnoyaDepartment of Molecular and Cell Biology, University of California, Berkeley, CA 94720bDivision of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA 02115cDepartment of Microbiology, Harvard Medical School, Boston, MA 02115dHHMI, Bethesda, MD 20815eDepartment of Plant and Microbial Biology, University of California, Berkeley, CA 94720
Proceedings of the National Academy of Sciences, 24.04.2024
Tilføjet 24.04.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 17, April 2024.
Læs mere Tjek på PubMedXing LiuChunchun ZhuShuke JiaHongyan DengJinhua TangXueyi SunXiaoli ZengXiaoyun ChenZixuan WangWen LiuQian LiaoHuangyuan ZhaXiaolian CaiWuhan XiaoaKey Laboratory of Breeding Biotechnology and Sustainable Aquaculture, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan 430072, ChinabHubei Hongshan Laboratory, Wuhan 430070, ChinacThe Innovation of Seed Design, Chinese Academy of Sciences, Wuhan 430072, ChinadUniversity of Chinese Academy of Sciences, Beijing 100049, ChinaeThe Key laboratory of Aquaculture Disease Control, Ministry of Agriculture, Wuhan 430072, China
Proceedings of the National Academy of Sciences, 24.04.2024
Tilføjet 24.04.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 17, April 2024.
Læs mere Tjek på PubMedJournal of Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Abstract Background K. pneumoniae is capable of resistance to β-lactam antibiotics through expression of β-lactamases (both chromosomal and plasmid-encoded) and downregulation of outer membrane porins. However, the extent to which these mechanisms interplay in a resistant phenotype is not well understood. The purpose of this study was to determine the extent to which β-lactamases and outer membrane porins affected β-lactam resistance.Methods MICs to β-lactams and inhibitor combinations were determined by agar dilution or E-test. Outer membrane porin production was evaluated by western blot of outer membrane fractions. β-lactamase carriage was determined by whole genome sequencing and expression evaluated by RT-qPCR.Results Plasmid-encoded β-lactamases were important for cefotaxime and ceftazidime resistance. Elevated expression of chromosomal SHV was important for ceftolozane/tazobactam resistance. Loss of outer membrane porins was predictive of meropenem resistance. ESβLs and pAmpCs in addition to porin loss were sufficient to confer resistance to the third generation cephalosporins, pipercillin/tazobactam, ceftolozane/tazobactam, and meropenem. pAmpCs (CMY-2 and DHA) alone conferred resistance to pipercillin/tazobactam.Discussion Detection of a resistance gene by whole genome sequencing was not sufficient to predict resistance to all antibiotics tested. some β-lactam resistance was dependent on the expression of both plasmid-encoded and chromosomal β-lactamases and loss of porins.
Læs mere Tjek på PubMedDaniele Focosi, Massimo Franchini, Arturo Casadevall, Fabrizio Maggi
Clinical Microbiology and Infection, 24.04.2024
Tilføjet 24.04.2024
Anti-Spike monoclonal antibodies represent one of the most tolerable prophylaxis and therapies for COVID-19 in frail and immunocompromised patients. Unfortunately, viral evolution in Omicron has led all of them to failure.
Læs mere Tjek på PubMedAnca Rath, Bärbel Kieninger, Nilufarbayim Mirzaliyeva, Stephan Schmid, Patricia Mester, Wulf Schneider-Brachert
Clinical Microbiology and Infection, 24.04.2024
Tilføjet 24.04.2024
Surveillance of multidrug-resistant bacteria like vancomycin-resistant enterococci (VRE) and prompt outbreak recognition are vital for infection prevention and control (IPC). Yet, data collection is laborious, and analysis prone to errors due to limited resolution of common diagnostic tools. Precision in defining \'the same pathogen\' is, however, critical for nosocomial transmission analysis.
Læs mere Tjek på PubMedBMC Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Abstract Background Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a major public health problem, necessitating the administration of polymyxin E (colistin) as a last-line antibiotic. Meanwhile, the mortality rate associated with colistin-resistant K. pneumoniae infections is seriously increasing. On the other hand, importance of administration of carbapenems in promoting colistin resistance in K. pneumoniae is unknown. Case presentation We report a case of K. pneumoniae-related pyogenic liver abscess in which susceptible K. pneumoniae transformed into carbapenem- and colistin-resistant K. pneumoniae during treatment with imipenem. The case of pyogenic liver abscess was a 50-year-old man with diabetes and liver transplant who was admitted to Abu Ali Sina Hospital in Shiraz. The K. pneumoniae isolate responsible for community-acquired pyogenic liver abscess was isolated and identified. The K. pneumoniae isolate was sensitive to all tested antibiotics except ampicillin in the antimicrobial susceptibility test and was identified as a non-K1/K2 classical K. pneumoniae (cKp) strain. Multilocus sequence typing (MLST) identified the isolate as sequence type 54 (ST54). Based on the patient’s request, he was discharged to continue treatment at another center. After two months, he was readmitted due to fever and progressive constitutional symptoms. During treatment with imipenem, the strain acquired blaOXA−48 and showed resistance to carbapenems and was identified as a multidrug resistant (MDR) strain. The minimum inhibitory concentration (MIC) test for colistin was performed by broth microdilution method and the strain was sensitive to colistin (MIC
Læs mere Tjek på PubMedBMC Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Abstract Background The problem of resistance to beta-lactam antibiotics, which is caused by ESBL and AmpC β-lactamases, is getting worse globally. Infections caused by bacterial isolates harboring these enzymes are difficult to treat with carbapenems being the sole effective treatment option for such infections. The objective of this study was to determine the frequency of ESBLs and AmpC-producing Gram-negative bacilli isolated from clinical specimens and to evaluate the sensitivity of cefepime-tazobactam combination against them. Methods This is an observational cross-sectional study carried out on 100 Gram-negative bacilli at Theodor Bilharz Research Institute Hospital during the period from February 2015 to January 2016. ESBL production was screened by using the disc diffusion test followed by confirmation by the combined disc confirmatory test, the screening for AmpC production was conducted using the cefoxitin disc test, which was subsequently confirmed by the AmpC disc test. Isolates confirmed positive for ESBL and/ or AmpC production were investigated for their susceptibility to antibiotics. Results Among 100 Gram-negative bacilli, 44 isolates were confirmed as ESBL producers by the combined disc confirmatory test out of 56 isolates that tested positive for ESBL production through the disc diffusion test. The presence of AmpC production was assessed using the cefoxitin disc test, 32 isolates were screened to be AmpC producers, and the AmpC disc test confirmed AmpC production in 9 isolates of them. Using the Mast® D68C set, 32 isolates were ESBL producers, 3 were AmpC producers, and 4 isolates were ESBL/AmpC co-producers. The highest sensitivity was to cefepime-tazobactam (91.48%) followed by the carbapenems. Conclusion Cefepime-tazobactam showed remarkable activity against ESBL and/or AmpC-producing Gram-negative bacilli and may be considered as a therapeutic alternative to carbapenems.
Læs mere Tjek på PubMedBMC Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Abstract Background Influenza-like illness (ILI) imposes a significant burden on patients, employers and society. However, there is no analysis and prediction at the hospital level in Chongqing. We aimed to characterize the seasonality of ILI, examine age heterogeneity in visits, and predict ILI peaks and assess whether they affect hospital operations. Methods The multiplicative decomposition model was employed to decompose the trend and seasonality of ILI, and the Seasonal Auto-Regressive Integrated Moving Average with exogenous factors (SARIMAX) model was used for the trend and short-term prediction of ILI. We used Grid Search and Akaike information criterion (AIC) to calibrate and verify the optimal hyperparameters, and verified the residuals of the multiplicative decomposition and SARIMAX model, which are both white noise. Results During the 12-year study period, ILI showed a continuous upward trend, peaking in winter (Dec. - Jan.) and a small spike in May-June in the 2–4-year-old high-risk group for severe disease. The mean length of stay (LOS) in ILI peaked around summer (about Aug.), and the LOS in the 0–1 and ≥ 65 years old severely high-risk group was more irregular than the others. We found some anomalies in the predictive analysis of the test set, which were basically consistent with the dynamic zero-COVID policy at the time. Conclusion The ILI patient visits showed a clear cyclical and seasonal pattern. ILI prevention and control activities can be conducted seasonally on an annual basis, and age heterogeneity should be considered in the health resource planning. Targeted immunization policies are essential to mitigate potential pandemic threats. The SARIMAX model has good short-term forecasting ability and accuracy. It can help explore the epidemiological characteristics of ILI and provide an early warning and decision-making basis for the allocation of medical resources related to ILI visits.
Læs mere Tjek på PubMedBMC Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Abstract Background Vaccination is effective in preventing viral respiratory infectious diseases through protective antibodies and the gut microbiome has been proven to regulate human immunity. This study explores the causal correlations between gut microbial features and serum-specific antiviral immunoglobulin G (IgG) levels. Methods We conduct a two-sample bidirectional Mendelian randomization (MR) analysis using genome-wide association study (GWAS) summary data to explore the causal relationships between 412 gut microbial features and four antiviral IgG (for influenza A, measles, rubella, and mumps) levels. To make the results more reliable, we used four robust methods and performed comprehensive sensitivity analyses. Results The MR analyses revealed 26, 13, 20, and 18 causal associations of the gut microbial features influencing four IgG levels separately. Interestingly, ten microbial features, like genus Collinsella, species Bifidobacterium longum, and the biosynthesis of L-alanine have shown the capacity to regulate multiple IgG levels with consistent direction (rise or fall). The reverse MR analysis suggested several potential causal associations of IgG levels affecting microbial features. Conclusions The human immune response against viral respiratory infectious diseases could be modulated by changing the abundance of gut microbes, which provided new approaches for the intervention of viral respiratory infections.
Læs mere Tjek på PubMed